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Abstract
For the last couple of decades, there has been a significant growth in sequencing data, lead-
ing to an extraordinary increase in the number of gene variants. This places a challenge on
the bioinformatics research community to develop and improve computational tools for func-
tional annotation of new variants. Genes coding for epigenetic regulators have important
roles in cancer pathogenesis and mutations in these genes show great potential as clinical
biomarkers, especially in hematologic malignancies. Therefore, we developed a model that
specifically focuses on these genes, with an assumption that it would outperform general
models in predicting the functional effects of amino acid substitutions. EpiMut is a stand-
alone software that implements a sequence based alignment-free method. We applied a
two-step approach for generating sequence based features, relying on the biophysical and
biochemical indices of amino acids and the Fourier Transform as a sequence transformation
method. For each gene in the dataset, the machine learning algorithm–Naïve Bayes was
used for building a model for prediction of the neutral or disease-related status of variants.
EpiMut outperformed state-of-the-art tools used for comparison, PolyPhen-2, SIFT and
SNAP2. Additionally, EpiMut showed the highest performance on the subset of variants
positioned outside conserved functional domains of analysed proteins, which represents an
important group of cancer-related variants. These results imply that EpiMut can be applied
as a first choice tool in research of the impact of gene variants in epigenetic regulators,
especially in the light of the biomarker role in hematologic malignancies. EpiMut is freely
available at https://www.vin.bg.ac.rs/180/tools/epimut.php.
Introduction
Epigenetic modifiers are unique players in cancer pathogenesis. Mutations in these genes can
alter the epigenetic landscape of many genes along with their expression, which affects key dis-
ease related pathways, including metabolic and apoptotic [1]. Cancers that are most connected
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with mutations in epigenetic factors are hematologic malignancies, which seem to represent
“epigenetic diseases”–diseases driven by mutations in regulators of DNA modifications and
post-translational modifications of histones [2]. Hematologic malignancies include lymphoid
malignancies, such as plasma cell neoplasms, various lymphomas and lymphoid leukemias,
and myeloid malignancies, such as acute myeloid leukemia (AML), myeloproliferative neo-
plasms and myelodysplastic syndrome. These diseases affect approximately 32 individuals per
100 thousand [3], with an average 5-year survival rate of 57% for lymphoid and 37% for mye-
loid neoplasms [4, 5]. Hematologic cancers are associated with age [3, 6, 7], which, considering
the remarkable increase in global life expectancy in humans over the past decades [8], puts
them in focus as an important and growing health issue.
Epigenetic factors include chromatin remodelling proteins, their cofactors, histones, his-
tone chaperones and proteins that affect gene expression as a reaction to the DNA or RNA
modifications. Epigenetic factors are comprehensively catalogued in the EpiFactors database
[9]. Somatic mutations in these genes contribute to the onset and progression of hematologic
malignancies and in many cases they represent markers associated with prognosis and
response to therapies [10]. Mutations in DNMT3A, IDH1/2 and ASXL1 are promising candi-
dates for the risk stratification parameters in AML patients [11], whereas mutations in four
epigenetic factors, EZH2, ARID1A, EP300 and CREBBP, were annotated as risk stratification
markers in follicular lymphoma [12]. Additionally, mutations in DNMT3A and TET2 can
contribute to prediction of the response to therapy in myeloid malignancies [13, 14]. Muta-
tions in DNMT3A, ASXL1, RUNX1, TP53, EZH2, CREBBP and EP300 are associated with the
survival of patients with various hematologic malignancies [13, 15–17].
Cancer related somatic mutations are archived in the COSMIC (Catalogue of Somatic
Mutations in Cancer) database [18]. Numerous epigenetic factors are catalogued in the COS-
MIC Gene Census, a list of genes with mutations that are causally implicated in cancer. How-
ever, there are several variations in these particular genes that do not represent somatic disease
related mutations, yet they are neutral and frequently present in healthy individuals. Neverthe-
less, the human genome has on average approximately 10,000–11,000 non-synonymous varia-
tions in the coding regions [19]. Thus far, gene variations that are most frequently linked to
human diseases are single nucleotide variations that lead to amino acid substitutions (AAS),
and therefore the major focus in the field is placed on the computational tools that can auto-
matically assess the potential impact of AAS on protein functions and their association with
human diseases [20–22]. Most computational tools for functional annotation of AAS rely on
the evolutionary concepts that deem amino acid positions conserved across multiple species as
functionally important. Therefore, the majority of these tools use multiple sequence align-
ments (MSA) as a starting point for determining AAS at the conserved positions which can
lead to annotations of these AAS as deleterious. SIFT [23] is a tool that bases its predictions
solely on MSA, while many others, including PolyPhen-2 [24], PROVEAN [25], MutationTa-
ster2 [26], PON-P2 [27], SNAP2 [28], etc., combine evolutionary information with sequence
and structure data. PolyPhen-2, which is the most widely used tool, adopts the Naïve Bayes
classifier with eight sequence-based and three structure-based features.
MSA-based methods do not scale well with the large amount of data gathered with the new
sequencing methodologies [29, 30] and, additionally, there is increasing evidence that conser-
vation-based inference does not correlate highly with protein sequence positions related to
functional tuning [31], which puts a focus on alternative approaches, like alignment-free meth-
ods. These methods are primarily used for DNA and protein sequence comparison, conse-
quently leading to development of many tools for genome-wide phylogeny, detection of
regulatory elements in DNA, detection of horizontal gene transfer and protein sequence classi-
fication [32]. Computational efficacy of alignment-free methods can be illustrated with a
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Protein Map, a method for protein sequence comparison based on the vector representation of
protein sequences using amino acid physicochemical characteristics, which is 13 times faster
than comparable MSA-based methods [33]. Alignment-free methodology is not commonly
used for this purpose and, according to the best of our knowledge, the only tool based on this
approach is SNAP2noali [28]. In our study, we developed an alignment-free method for esti-
mating the effects of AAS–EpiMut.
Methods
Dataset
The dataset encompassed the epigenetic modifier genes that fulfil the following criteria: 1) are
included in the COSMIC list of Cancer Gene Census for Haematopoietic and Lymphoid Tis-
sue 2) are included in the EpiFactors database and 3) have more than 50 AAS in dbSNP [34]
and COSMIC—Haematopoietic and Lymphoid Tissue, in total (Fig 1). Thus, sequences of 19
epigenetic regulators were obtained from the UniProt database [35], in the FASTA format.
Conserved functional domains in these genes were retrieved from the Pfam database (version
31.0) [36].
Cancer associated mutation data were collected from the COSMIC database (v81). In the
dataset, only SNPs from the reference transcripts of genes were included and, also, we included
only SNPs satisfying criteria: “Chrom. Sample Cnt.” > = 100 AND “Variant allele frequency”
> = 0.001 in the dbSNP (b151). We excluded ambiguous variants. The data collected from the
databases didn’t contain any personal information.
EpiMut features and scores
We used a two-step approach for generating sequence based features (Fig 2). First, we con-
ducted amino acid encoding of protein sequences. Encoding was done using indexes stored in
the AAIndex, a comprehensive archive of various biochemical and biophysical amino acid
indices [37]. We employed each of the 553 indices (out of 566) that had values for all amino
acids. In the second step, we performed a Fourier Transform on each numerical representation
of protein sequences. The Fourier Transform decomposes a numerical sequence into periodi-
cal functions, with series of frequencies and their amplitudes, represented by the informational
Fig 1. Selection of genes, using the COSMIC Cancer Gene Census—Haematopoietic and Lymphoid Tissue and
EpiFactors database. There were at least 50 AAS in dbSNP and COSMIC for each of these 19 selected genes (in the
red circle) that further constituted our dataset.
https://doi.org/10.1371/journal.pone.0244948.g001
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spectrum [38]. Frequencies in the informational spectrum correspond to the distribution of
structural motifs and we used this property to predict the effects of sequence variation on pro-
tein function.
Therefore, each wild type protein sequence was firstly transformed into 553 numerical
sequences that were subsequently converted into 553 informational spectra by the Fourier
Transform. An informational spectrum frequency with the highest amplitude value was
selected for generation of EpiMut scores. The EpiMut score is defined as the difference
between the amplitude value on the selected frequency in the sequence with the variant and
the amplitude value on that particular frequency of the wild type. Therefore, each variant was
represented with the vector encompassing 553 scores, as follows:
Vi ¼ ½Sið1Þ; . . . ; SiðMÞ�
SiðjÞ ¼ A
vari




j Þ; i ¼ 1; 2; . . . ;N; j ¼ 1; 2; . . . ;M
where fj� is the frequency of the peak with the highest value of the amplitude in the informa-





) are the amplitudes on the frequency fj
�
of the i-th variant and wild type informational
spectra accordingly generated using the j-th AA index; Si(j) is the j-th EpiMut score (defined
by the j-th AA index encoder) between the i-th variant and wild type; Vi is the 553 dimensional
vector that represents the i-th variant; N is the number of variants in one protein from our
dataset and it varies depending on the protein; and M is the number of used indices for amino
acid encoding and it equals 553.
EpiMut models and predictions
EpiMut relies on the Naïve Bayes classifier, built for each protein in the dataset, to generate
predictions (Fig 2). We used the H2O platform for machine learning [39]. The Naïve Bayes
algorithm implementation in H2O [40] was used for training and building the classification
models. The dimensionality of training and test data was reduced through the use of the back-
ward elimination process, the GreedyStepwise method, which performed the attribute selec-
tion, whereas for the evaluation of the attributes, the WrapperSubsetEval algorithm, from the
Weka 3.8.1 environment [41], was applied. EpiMut was trained and validated using 10-fold
cross-validation.
Fig 2. EpiMut procedure that was applied to each of the 19 proteins in the dataset.
https://doi.org/10.1371/journal.pone.0244948.g002
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Performance evaluation
We estimated the performance of the tested tools using various measures, which are based on:
true positives (TP)–correctly predicted disease related variants, false positives (FP)–neutral
substitutions incorrectly predicted to be disease-related, true negatives (TN)–correctly pre-
dicted neutrals and false negatives (FN)–disease-related variants incorrectly predicted to be
neutral. We calculated the sensitivity, specificity and accuracy as follows:
Sensitivity ¼ TP=ðTP þ FNÞ
Specificity ¼ TN=ðTN þ FPÞ
Accuracy ¼ ðTP þ TNÞ=ðTP þ TN þ FPþ FNÞ
Performance was additionally measured with the Matthews Correlation Coefficient (MCC):
MCC ¼
ðTP � TN   FP � FNÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðTPþ FPÞ � ðTPþ FNÞ � ðTN þ FPÞ � ðTN þ FNÞ
p
Finally, we generated the Receiver Operating Characteristic (ROC) curves and calculated
areas under the ROC curves (AUC). A ROC curve shows the relative trade-off between the
true positive rate and false positive rate when different thresholds are set to distinguish
between the two classes and it is widely used as a measure of performance of binary classifiers.
For each statistic, the standard deviation (SD) was calculated as the difference between the
value of the statistic for each gene (gi) and the overall performance (gall). The standard error














Comparison with other prediction tools
For the comparison of EpiMut with other tools for functional annotation of AAS, we used
SIFT, PolyPhen-2 and SNAP2. SIFT uses sequence homology to predict the effect of an AAS
on the protein function, considering the position at which the substitution occurred and the
type of amino acid change. It calculates the probability score that indicates if the amino acid
change is tolerated. In this study, we had to transform SIFT scores so they could be compared
with other tools and we calculated the SIFTscore = 1 –SIFTscore�, where the SIFTscore� is the
score originally retrieved from the SIFT tool. This transformation resulted in higher SIFT
scores for disease-associated variants, and vice versa for neutral variants, which is in accor-
dance with scores of the other three tools and could be applied to the calculation of comparable
ROC curves. We used the single protein tool SIFT Sequence, with default values of median
conservation of sequences (3.0). The PSI-BLAST search was applied to the UniRef90 database
and sequences with a similarity level of 90% or more to the query sequence were removed
from the alignment. Binary classification was done by annotating AAS with the
SIFTscore > 0.95 as disease-related and AAS with a SIFTscore < 0.95 as neutral. Variants with
a SIFTscore = 0.95 were classified as in output provided by the SIFT tool. The PolyPhen-2
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bases its predictions of the damaging effects of missense mutations on eight sequence-based
features (PSIC score of the wild-type amino acid, difference between the PSIC scores of the
wild type and the mutant amino acids, the sequence identity to the closest homologue, congru-
ency of the mutant allele to the multiple alignment, CpG context, alignment depth, change in
the amino acid volume, whether the site of the mutation resides within an annotated Pfam
domain) and three structure-based features (the accessible surface area, the change in the
hydrophobic propensity, crystallographic B-factor. The functional effect of an AAS is predicted
based on the calculated Naïve Bayes probabilistic score. A variant is automatically classified as
“probably damaging”, “possibly damaging” or “benign”. For this study we adopted a binary clas-
sification, with a cut-off for a probabilistic score of 0.5, leading to annotating AAS with the
higher scores as disease-related and those with lower scores as neutral. We used default values
for query options and the HumVar-trained version of PolyPhen-2. SNAP2 is a neural networks
based classifier. Its feature selection and training was done using various features, like biophysi-
cal amino acid properties, amino acid properties as provided by the AAindex database, explicit
sequence, PSIC profiles, secondary structure and solvent accessibility, residue flexibility, SWIS-
S-PROT annotations, residue annotations from Pfam and PROSITE, predicted binding resi-
dues, predicted disordered regions, proximity to the N- and C-terminus, statistical contact
potentials, co-evolving positions and low-complexity regions. SNAP2 predicts the effect of a sin-
gle AAS on protein function and it gives a binary prediction “effect”/“neutral” and a score rang-
ing from -100 (strong neutral prediction) to +100 (strong effect prediction), which reflects the
likelihood of this specific variation altering the native protein function.
Results
Gene specific models versus multiple genes model
We collected variants from COSMIC and dbSNP for 19 epigenetic factors mutated in hemato-
logic malignancies. Our dataset contained 1303 disease-related and 1578 neutral variants
(Table 1). The entire variants dataset is provided in the S1 Table in S1 File.
Two types of prediction models were built: (i) gene specific models (GSM) that comprise
the feature selection and training process separately for each gene in the dataset, and (ii) the
multiple genes model (MGM), one general model built for all variants in the dataset. In both
approaches, the features were generated based on amino acid indices listed in the AAindex
and using the Fourier Transform, as described in the Methods section, while Naive Bayes was
used as the machine learning algorithm.
The comparison of prediction capacities of these two approaches showed that the GSM
method outperformed the MGM (Fig 3) and thus, the GSM was selected for further use in cre-
ating the EpiMut tool. Selected features in the GSM procedure for each of the 19 proteins are
shown in the S2 Table in S1 File.
Performance of EpiMut and comparison with state-of-the-art tools
Gene-specific and alignment-free methodology was used for the development of EpiMut, a
tool for functional annotation of AAS in 19 analysed epigenetic factors. It provides probabili-
ties for the predictions and the cut-off value of 0.5 was applied for binary classification, denot-
ing AAS with the value�0.5 as “MUT” in the case of a disease-related prediction and AAS
with the probability value <0.5 as “SNP” in the case of neutral predictions. We compared the
performance of EpiMut with three state-of-the-art tools for functional annotation of AAS,
PolyPhen-2, SIFT and SNAP2. Performance was measured using Sensitivity, Specificity, Accu-
racy and MCC. EpiMut showed a better performance compared to PolyPhen-2, SIFT and
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PLOS ONE | https://doi.org/10.1371/journal.pone.0244948 January 4, 2021 6 / 17
SNAP2 for each of these measures and, additionally, outperformed these tools in regards to
AUC (Fig 4).
Detailed comparison of methods performance was focused on the correctly classified muta-
tions. In this step, we contrasted EpiMut to other methods and identified mutations that
within each comparison were exclusively recognized by only one method and denoted those
exclusive TPs. Noticeably, each of the methods reveals some of the mutations that were unob-
served by the other one, but EpiMut is significantly dominant over its competitors (Fig 5).
This analysis demonstrates that EpiMut improves our capacity to acquire new knowledge and
accelerates experimental investigations in this complex field.
Table 1. The variants dataset consisted of 2881 variants in 19 epigenetic factors.
Gene Disease-related variants Neutral variants Total number of variants
ARID1A 23 68 91
ASXL1 21 70 91
ATM 95 163 258
ATRX 48 56 104
BCOR 23 29 52
CREBBP 73 70 143
DNMT3A 111 14 125
EP300 68 88 156
EZH2 69 9 78
JAK2 40 41 81
KMT2A 34 90 124
KMT2C 96 251 347
KMT2D 84 208 292
NSD1 48 85 133
SETD2 29 104 133
SF3B1 49 5 54
SPEN 23 141 164
TET2 202 67 269
TP53 167 19 186
1303 1578 2881
https://doi.org/10.1371/journal.pone.0244948.t001
Fig 3. Comparison between the variant effect predictor based on Gene Specific Models (GSM) and the Multiple
Genes Model (MGM).
https://doi.org/10.1371/journal.pone.0244948.g003
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Further on, we inspected closely a set of variants miss-predicted by three out of four tools,
which were labelled “difficult to predict mutations” (DTP). In the original dataset 12.4% (162
variants) were DTP disease-related variants. PolyPhen-2 correctly predicted 21, SIFT 24,
SNAP2 21 and EpiMut 96 of these cases (Fig 6). To further investigate these 162 mutations, we
searched available literature for additional information and the experimental evidence about
their effects in obstructing the proteins’ normal functions and their involvement in human dis-
eases. For the majority of these mutations, besides the information that they are associated
with the disease, there was no detailed data about their effects on the protein function. This led
us to focus further investigation on the three variations for which there was some detailed
information regarding their effects in the available literature.
Further, we focused on two genes and the following variants: A1505T in TET2 and S46F
and D48N in TP53 that were predicted as disease-related by EpiMut only. According to the lit-
erature, the TET2 mutation A1505T severely reduces the TET2 ability to bind protein WT1
[42]. WT1, a transcription factor involved in normal embryonic development of urogenital
and hematopoietic systems, plays an important role in pathogenesis of hematologic malignan-
cies, especially acute leukemias [43]. WT1 acts either as a tumour suppressor or oncogene
depending on the cellular context and PPIs [44, 45]. Wang et al. showed that WT1 physically
Fig 4. Performance of EpiMut, PolyPhen-2, SIFT and SNAP2 on a dataset consisting of variants in epigenetic
factors mutated in hematologic malignancies.
https://doi.org/10.1371/journal.pone.0244948.g004
Fig 5. EpiMut is contrasted to SIFT, PolyPhen-2 and SNAP2 in the search for unshared correctly classified
mutations. Stacked bars represent the numbers of exclusive TPs in each of the three comparisons.
https://doi.org/10.1371/journal.pone.0244948.g005
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interacts with wild type TET2 and recruits it to its target genes, which affects expression of
these genes and leads to inhibition of leukemia cell proliferation [42]. The A1505T mutation
in TET2 disrupts this interaction, consequently leading to an effect on WT1 target genes
expression and increased leukemia cell proliferation [42]. TET2 is frequently mutated in the
majority of hematologic cancers, with a frequency of 17–37% in myeloid and 15–33% in T-cell
lymphoid malignancies [46], and the disruption of its PPIs by mutations can be an important
mechanism of its pathological role in these cases.
The second DTP we focused on is within TP53, a well-described tumour suppressor with
roles in cell cycle regulation and apoptosis, which is mutated in many cancer types. In hemato-
logic malignancies, the frequency of TP53 mutations ranges from 3–8% in AML to 10–20% in
chronic lymphocytic leukemia [47]. More importantly, mutations in TP53 in hematologic can-
cers are associated with a more aggressive disease, worse overall survival and resistance to ther-
apies [47]. Enari et al. showed that the S46F mutation in TP53 increases its binding to clathrin,
a protein involved in vesicle transport [48]. This interaction is involved in apoptosis, although
the mechanism remains elusive [48, 49]. Nevertheless, it was previously shown that
impairment of clathrin’s normal functions, through gene fusions, leads toward various lym-
phoid malignancies [49].
Finally, aspartic acid at position 48 resides in the TAD2 domain of protein TP53 and is
involved in the interaction with the Taz2 domain of histone acetyltransferase EP300 [50],
another protein in our dataset. EP300 is an important player in pathogenesis of various lym-
phoid malignancies and its mutations are valuable biomedical markers in these diseases [12,
16]. TP53-EP300 interaction results in stabilization of TP53, its decreased degradation and
increased gene transcription. Mutation D48N in TP53 reduces this interaction [50] and can
consequently affect all of the mentioned functions and underlie pathogenic phenotypes [51].
According to the aforementioned findings, EpiMut efficiently identifies variants that disrupt
protein interactions and support biological processes that underlie the disease mechanisms.
Fig 6. Distribution per gene of 162 “difficult to predict mutations” (DTP) predicted by EpiMut, PolyPhen-2, SIFT
and SNAP2.
https://doi.org/10.1371/journal.pone.0244948.g006
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Performance on the subset of variants positioned outside conserved
functional domains
Although evolutionary based methodologies are almost ubiquitously used in tools for func-
tional annotation of AAS, our previous research showed that SIFT and PolyPhen-2 have low
sensitivity (51% and 39%, respectively) in predicting the functional effects of variants in pro-
tein regions of epigenetic modifiers that are outside of the conserved functional domains
(CFD) [52]. It is important to address this issue since 50% of AAS associated with cancers were
shown to be positioned in these non-CFDs (nCFD) [53]. Therefore, we tested the performance
of EpiMut, PolyPhen-2, SIFT, and SNAP2 on the subset of 2108 nCFD variants (Table 2).
The decrease in performance on the nCFD dataset was observed for all prediction tools (Fig
7), whereas EpiMut shows the smallest decrease in accuracy, MCC and it retains a similar
value of AUC, which is a consequence of the high increase in specificity (Fig 7). The perfor-
mance of all tools on the nCFD dataset is shown in S1 Fig in S1 File, with EpiMut showing the
best performance for all measures except sensitivity.
EpiMut standalone tool
EpiMut software is implemented in the JAVA language, using the H2O library for generating
machine learning classifiers, and is available as a standalone application, which can be exe-
cuted on any operating system containing the Java Virtual Machine.
EpiMut supports a batch mode query for separate genes. The input file has to contain a list
of AAS in the form of:
original_amino_acid position_in_protein substitute_amino_acid (example: G187V)
and the gene name of the selected gene for the query in the input file name. The generated out-
put file contains the name of the query gene in the file name and the list of AAS with predicted
Table 2. nCFD dataset consisting of 2108 variants in non-conserved regions of epigenetic factors.
Gene Disease-related variants Neutral variants Total number of variants
ARID1A 18 62 80
ASXL1 20 64 84
ATM 53 125 178
ATRX 39 52 91
BCOR 12 24 36
CREBBP 22 59 81
DNMT3A 51 10 61
EP300 36 77 113
EZH2 31 8 39
JAK2 14 22 36
KMT2A 29 83 112
KMT2C 86 232 318
KMT2D 64 199 263
NSD1 41 84 125
SETD2 22 104 126
SF3B1 48 5 53
SPEN 20 129 149
TET2 105 45 150
TP53 6 7 13
717 1391 2108
https://doi.org/10.1371/journal.pone.0244948.t002
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class–SNP for neutral and MUT for disease-related variants, as well as probability associated
with the prediction.
EpiMut is a free software released under the Apache License, Version 2.0. The EpiMut
application with documentation is available at https://www.vin.bg.ac.rs/180/tools/epimut.php.
Discussion
Machine learning (ML) methods are widely used for solving various biological classification
problems, including inferring about the disease-related/neutral effects of AAS. The most com-
monly used approaches are support vector machines, neural networks, Bayesian classifiers,
random forests and decision trees [54]. Two out of three tools that we used for performance
comparison are ML-based–PolyPhen-2 employed Naïve Bayes and SNAP2 employed the neu-
ral networks approach. EpiMut encompasses a selection of different features and the Naive
Bayes method as part of the GSM approach and thus it differs from the other tools. Compari-
son of the GSM strategy and commonly used approach of one ubiquitous model for all genes–
the MGM model, showed that GSM-based EpiMut significantly outperforms MGM. This find-
ing is in accordance with previous research showing that applying gene-specific thresholds to
the results of standard tools, like PolyPhen-2, SIFT, Mutation Taster, Mutation Assessor [55],
CADD [56], may improve their prediction performance [57, 58]. On the other hand, gene- or
disease-specific models that are trained on relatively restricted but specific datasets satisfacto-
rily associate gene variants with hyperthrophic cardiomyopathy [59], haemophilia [60] and
various cardiac diseases [61]. The GSM approach that we developed employs variants collec-
tion of similar sizes as various previously developed methods for prediction of variant func-
tional significance in: RET [62, 63], GLA [64] and DPYD [65]. It is important to notice that
many previous studies also showed that the Bayesian approach is the method of choice for the
prediction of effects of AAS when only small datasets are available [61, 62, 66]. Superiority of
the GSM over the MGM points to a gene specific approach as the strategy for improving tools
for functional annotation of gene variants and directions for the future development of this
research field.
Performances of the PolyPhen-2 and SIFT on the variant dataset used in this study are simi-
lar to the results obtained in the study by Thusberg et al. [20], in which the authors evaluated
Fig 7. Differences in performance of EpiMut, PolyPhen-2, SIFT and SNAP2 between the entire variants dataset
and nCFD data subset. Each column in this histogram represents the difference among the values of a particular
performance measure obtained, for each tool, on the entire variants dataset and the values obtained for the nCFD data
subset.
https://doi.org/10.1371/journal.pone.0244948.g007
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various tools on the dataset containing approximately 40 thousand human AAS. The SNAP2
performance on our variant dataset was similar to the reported performance by the authors of
the tool [28]. EpiMut showed a significant advantage in performance compared to these state-
of-the-art tools for functional annotation of AAS. Accuracy of EpiMut was higher by 7.4% on
average compared to other tools, while the AUC was higher by 8.0% on average. Nevertheless,
one should bear in mind that different approaches underlying PolyPhen-2, SIFT, SNAP2 and
EpiMut and especially various datasets that were used for the training of ML-based tools, make
these comparisons difficult [54] given that the presence of a protein in a training dataset
improves its performance for predicting the effects of different variants in the same protein
[67]. In case of PolyPhen-2, 16 out of 19 proteins from our dataset were in its training set.
Additionally, 36 variants in our dataset were already present in the PolyPhen-2 training set
and it performed significantly better in predicting their effects compared to its average
performance.
An important advantage of EpiMut which underlies its better performance on the nCFD
dataset is that it doesn’t rely on the evolutionary information. Compared to other tools EpiMut
has 8.5% higher accuracy and 14.4% higher AUC, on average. Lower accuracy of PolyPhen-2,
SIFT and SNAP2 on the nCFD compared to the CFD set (14%, 13% and 20%, respectively) is
in line with our previous results showing that MSA-based tools are not efficient for the predic-
tion of functional effects of AAS outside CFDs [52]. The importance of this result is reflected
in the fact that 55% of hematologic malignancy-related variants in analysed epigenetic factors,
as well as 73% of all variants in the dataset are in nCFD and they are, therefore, predicted with
lower efficacy by MSA-based tools.
Finally, approximately 12% of disease-related variants in our dataset were correctly pre-
dicted solely by one tool. Of these DTP variants, 60% were correctly predicted solely by Epi-
Mut, which emphasizes the importance of the EpiMut workbench, combining the alignment-
free and gene-specific approach. Almost none of the 162 DTP variants were previously func-
tionally annotated in detail. Nevertheless, there was previous experimental verification of func-
tional effects of three variants, in TET2 and TP53, showing their role in the PPI of these
proteins [42, 48, 50]. Our recent research has shown that features generated on the basis of
physicochemical characteristics of amino acids are important for understanding and predict-
ing PPI [68]. This implies that characteristics of certain amino acids and their surrounding
subsequences, captured through the use of the Fourier Transform for processing numerically
encoded sequences, play crucial roles in protein interactions. EpiMut captures the effects of
variants in these positions with high power. PPI interaction sites in the case of transient inter-
actions are not under high evolutionary pressure and they vary to a great extent, which enables
higher flexibility of these interactions [69]. This can have consequences in lower performance
of MSA-based methods in predicting the functional effects of mutations. Other cases of muta-
tions in epigenetic factors that alter PPI, playing an important role in pathogenesis of hemato-
logic malignancies, are mutations in the SET domain of EZH2. This domain is crucial for
EZH2 binding abilities [70] and mutations positioned in it contribute to the onset of lympho-
mas [71]. The result showing that EpiMut can correctly predict the majority of cases that were
wrongly annotated by other tools, indicates the complementarity of EpiMut and the studied
MSA-based tools, which can be used in the future for building new assembly methods.
It is worth noting that the methodology applied in this research, based on the gene-specific
and alignment-free approach, can be used for the analysis of any gene mutated in human dis-
eases. The only consideration that should be taken into account is the number of variants asso-
ciated with a gene, which must satisfy requirements of the machine learning algorithms.
Epigenetic factors in hematologic cancers provide a proof of concept and demonstrate the use-
fulness and effectiveness of the proposed approach. We provide EpiMut to serve the scientific
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community in predicting the functional effects of AAS and in future studies, we plan to further
extend the scope of this methodology to additional genes involved in human cancers.
Conclusions
Epigenetic factors are frequently mutated in hematologic malignancies and new variants are
being discovered at an unprecedented pace. Numerous variants in genes coding for epigenetic
regulators have already been identified as biomarkers for prognosis and therapy response, and
computational models that effectively distinguish neutral from disease variants are in great
demand. In this paper, we described a fast and computationally efficient EpiMut method that
significantly improves variants effect predictions. EpiMut, especially, exceeds state-of-the-art
tools in predicting the effects of difficult variants and functionally important variants posi-
tioned outside the conserved domains of proteins. The standalone EpiMut software that we
contribute to the community has the potential to advance whole genome sequencing analysis
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5. Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of Euro-
pean patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013; 98
(2): 230–238. https://doi.org/10.3324/haematol.2012.064014 PMID: 22983589
6. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence pat-
terns by WHO subtype in the United States, 1992–2001. Blood. 2006; 107(1): 265–276. https://doi.org/
10.1182/blood-2005-06-2508 PMID: 16150940
7. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type:
a report from the Haematological Malignancy Research Network. Br J Cancer. 2011; 105(11): 1684–
1692. https://doi.org/10.1038/bjc.2011.450 PMID: 22045184
8. Hassan M, Abedi-Valugerdi M. Hematologic malignancies in elderly patients. Haematologica. 2014; 99
(7): 1124–1127. https://doi.org/10.3324/haematol.2014.107557 PMID: 24986872
9. Medvedeva YA, Lennartsson A, Ehsani R, Kulakovskiy IV, Vorontsov IE, Panahandeh P, et al. EpiFac-
tors: a comprehensive database of human epigenetic factors and complexes. Database (Oxford). 2015;
2015: bav067. https://doi.org/10.1093/database/bav067 PMID: 26153137
10. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid
malignancies. Nat Rev Cancer. 2012; 12(9): 599–612. https://doi.org/10.1038/nrc3343 PMID:
22898539
11. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute
myeloid leukemia. Blood. 2013; 121(18): 3563–3572. https://doi.org/10.1182/blood-2013-01-451781
PMID: 23640996
12. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene
mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lym-
phoma: a retrospective analysis of a prospective clinical trial and validation in a population-based regis-
try. Lancet Oncol. 2015; 16(9): 1111–1122. https://doi.org/10.1016/S1470-2045(15)00169-2 PMID:
26256760
13. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. Gene mutation patterns and their prognostic
impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011; 118(20): 5593–5603.
https://doi.org/10.1182/blood-2011-03-343988 PMID: 21881046
14. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of inte-
grated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12): 1079–1089. https://
doi.org/10.1056/NEJMoa1112304 PMID: 22417203
15. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of
point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26): 2496–2506. https://doi.
org/10.1056/NEJMoa1013343 PMID: 21714648
16. Jiang Y, Hatzi K, Shaknovich R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood.
2013; 121(21): 4271–4279. https://doi.org/10.1182/blood-2012-12-451799 PMID: 23704048
17. Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A. Mutations of CREBBP and
SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the
SAKK 38/07 prospective clinical trial cohort. J Hematol Oncol. 2017; 10(1): 70. https://doi.org/10.1186/
s13045-017-0438-7 PMID: 28302137
18. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genet-
ics at high-resolution. Nucleic Acids Res. 2017; 45(D1): D777–D783. https://doi.org/10.1093/nar/
gkw1121 PMID: 27899578
19. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A
map of human genome variation from population-scale sequencing. Nature. 2010; 467(7319): 1061–
1073. https://doi.org/10.1038/nature09534 PMID: 20981092
20. Thusberg J, Olatubosun A, Vihinen M. Performance of mutation pathogenicity prediction methods on
missense variants. Hum Mutat. 2011; 32(4): 358–368. https://doi.org/10.1002/humu.21445 PMID:
21412949
21. Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z. Assessment of computational methods for pre-
dicting the effects of missense mutations in human cancers. BMC Genomics. 2013; 14 Suppl 3(Suppl
3): S7. https://doi.org/10.1186/1471-2164-14-S3-S7 PMID: 23819521
22. Zhao F, Zheng L, Goncearenco A, Panchenko AR, Li M. Computational Approaches to Prioritize Can-
cer Driver Missense Mutations. Int J Mol Sci. 2018; 19(7): 2113. https://doi.org/10.3390/ijms19072113
PMID: 30037003
PLOS ONE Functional annotation of amino acid substitutions in epigenetic factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0244948 January 4, 2021 14 / 17
23. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001; 11(5): 863–
874. https://doi.org/10.1101/gr.176601 PMID: 11337480
24. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server
for predicting damaging missense mutations. Nat Methods. 2010; 7(4): 248–249. https://doi.org/10.
1038/nmeth0410-248 PMID: 20354512
25. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitu-
tions and indels. PLoS One. 2012; 7(10): e46688. https://doi.org/10.1371/journal.pone.0046688 PMID:
23056405
26. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-
sequencing age. Nat Methods. 2014; 11(4): 361–362. https://doi.org/10.1038/nmeth.2890 PMID:
24681721
27. Niroula A, Urolagin S, Vihinen M. PON-P2: prediction method for fast and reliable identification of harm-
ful variants. PLoS One. 2015; 10(2): e0117380. https://doi.org/10.1371/journal.pone.0117380 PMID:
25647319
28. Hecht M, Bromberg Y, Rost B. Better prediction of functional effects for sequence variants. BMC Geno-
mics. 2015; 16 Suppl 8: S1. https://doi.org/10.1186/1471-2164-16-S8-S1 PMID: 26110438
29. Chan CX, Ragan MA. Next-generation phylogenomics. Biol Direct. 2013; 8: 3. https://doi.org/10.1186/
1745-6150-8-3 PMID: 23339707
30. Zielezinski A, Girgis HZ, Bernard G, Leimeister CA, Tang K, Dencker T, et al. Benchmarking of align-
ment-free sequence comparison methods. Genome Biol. 2019; 20(1): 144. https://doi.org/10.1186/
s13059-019-1755-7 PMID: 31345254
31. Miller M, Vitale D, Kahn PC, Rost B, Bromberg Y. funtrp: identifying protein positions for variation driven
functional tuning. Nucleic Acids Res. 2019; pii: gkz818. https://doi.org/10.1093/nar/gkz818 PMID:
31584091
32. Zielezinski A, Vinga S, Almeida J, Karlowski WM. Alignment-free sequence comparison: benefits, appli-
cations, and tools. Genome Biol. 2017; 18(1): 186. https://doi.org/10.1186/s13059-017-1319-7 PMID:
28974235
33. Yu C, Cheng SY, He RL, Yau SS. Protein map: an alignment-free sequence comparison method based
on various properties of amino acids. Gene. 2011; 486(1–2): 110–118. https://doi.org/10.1016/j.gene.
2011.07.002 PMID: 21803133
34. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of
genetic variation. Nucleic Acids Res. 2001; 29(1): 308–311. https://doi.org/10.1093/nar/29.1.308 PMID:
11125122
35. UniProt Consortium T. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2018; 46(5):
2699. https://doi.org/10.1093/nar/gky092 PMID: 29425356
36. Finn RD, Coggill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, et al. The Pfam protein families data-
base: towards a more sustainable future. Nucleic Acids Res. 2016; 44(D1): D279–D285. https://doi.org/
10.1093/nar/gkv1344 PMID: 26673716
37. Kawashima S, Pokarowski P, Pokarowska M, Kolinski A, Katayama T, Kanehisa M. AAindex: amino
acid index database, progress report 2008. Nucleic Acids Res. 2008; 36(Database issue): D202–D205.
https://doi.org/10.1093/nar/gkm998 PMID: 17998252
38. Veljkovic N, Glisic S, Prljic J, Perovic V, Botta M, Veljkovic V. Discovery of new therapeutic targets by
the informational spectrum method. Curr Protein Pept Sci. 2008; 9(5): 493–506. https://doi.org/10.
2174/138920308785915245 PMID: 18855700
39. H2O.ai (2018). H2O, H2O version 3.20.0.3. https://github.com/h2oai/h2o-3.
40. Hastie T, Tibshirani R, Friedman J, Franklin J. The elements of statistical learning: data mining, infer-
ence and prediction. The Mathematical Intelligencer. 2005; 27(2): 83–85.
41. Frank E, Hall MA, Witten IH. The WEKA Workbench. Online Appendix for "Data Mining: Practical
Machine Learning Tools and Techniques". Morgan Kaufmann, Fourth Edition; 2016.
42. Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, et al. WT1 recruits TET2 to regulate its target gene
expression and suppress leukemia cell proliferation. Mol Cell. 2015; 57(4): 662–673. https://doi.org/10.
1016/j.molcel.2014.12.023 PMID: 25601757
43. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haemato-
poiesis. Expert Rev Mol Med. 2007 May 24; 9(14):1–17. https://doi.org/10.1017/S1462399407000336
PMID: 17524167
44. Roberts SG. The modulation of WTI transcription function by cofactors. Biochem Soc Symp. 2006;
(73):191–201. https://doi.org/10.1042/bss0730191 PMID: 16626299
PLOS ONE Functional annotation of amino acid substitutions in epigenetic factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0244948 January 4, 2021 15 / 17
45. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leuke-
mia. 2007 May; 21(5):868–76. https://doi.org/10.1038/sj.leu.2404624 PMID: 17361230
46. Nakajima H, Kunimoto H. TET2 as an epigenetic master regulator for normal and malignant hematopoi-
esis. Cancer Sci. 2014 Sep; 105(9):1093–9. https://doi.org/10.1111/cas.12484 PMID: 25040794
47. Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in haematological malignancies. J Hema-
tol Oncol. 2013 Mar 27; 6:23. https://doi.org/10.1186/1756-8722-6-23 PMID: 23531342
48. Enari M, Ohmori K, Kitabayashi I, Taya Y. Requirement of clathrin heavy chain for p53-mediated tran-
scription. Genes Dev. 2006 May 1; 20(9):1087–99. https://doi.org/10.1101/gad.1381906 PMID:
16618797
49. Ybe JA. Novel clathrin activity: developments in health and disease. Biomol Concepts. 2014 May; 5
(2):175–82. https://doi.org/10.1515/bmc-2013-0040 PMID: 25372751
50. Miller Jenkins LM, Feng H, Durell SR, Tagad HD, Mazur SJ, Tropea JE, et al. Characterization of the
p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex. Biochemistry.
2015; 54(11): 2001–2010. https://doi.org/10.1021/acs.biochem.5b00044 PMID: 25753752
51. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating muta-
tions of acetyltransferase genes in B-cell lymphoma. Nature. 2011 Mar 10; 471(7337):189–95. https://
doi.org/10.1038/nature09730 PMID: 21390126
52. Gemovic B, Perovic V, Glisic S, Veljkovic N. Feature-based classification of amino acid substitutions
outside conserved functional protein domains. ScientificWorldJournal. 2013; 2013: 948617. https://doi.
org/10.1155/2013/948617 PMID: 24348198
53. Yue P, Forrest WF, Kaminker JS, Lohr S, Zhang Z, Cavet G. Inferring the functional effects of mutation
through clusters of mutations in homologous proteins. Hum Mutat. 2010; 31(3): 264–271. https://doi.
org/10.1002/humu.21194 PMID: 20052764
54. Vihinen M. How to evaluate performance of prediction methods? Measures and their interpretation in
variation effect analysis. BMC Genomics. 2012; 13 Suppl 4: S2. https://doi.org/10.1186/1471-2164-13-
S4-S2 PMID: 22759650
55. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer
genomics. Nucleic Acids Res. 2011; 39(17): e118. https://doi.org/10.1093/nar/gkr407 PMID: 21727090
56. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating
the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46(3): 310–315. https://doi.org/
10.1038/ng.2892 PMID: 24487276
57. Li Q, Liu X, Gibbs RA, Boerwinkle E, Polychronakos C, Qu HQ. Gene-specific function prediction for
non-synonymous mutations in monogenic diabetes genes. PLoS One. 2014; 9(8): e104452. https://doi.
org/10.1371/journal.pone.0104452 PMID: 25136813
58. Itan Y, Shang L, Boisson B, Ciancanelli MJ, Markle JG, Martinez-Barricarte R, et al. The mutation signif-
icance cutoff: gene-level thresholds for variant predictions. Nat Methods. 2016; 13(2): 109–110. https://
doi.org/10.1038/nmeth.3739 PMID: 26820543
59. Jordan DM, Kiezun A, Baxter SM, Agarwala V, Green RC, Murray MF, et al. Development and valida-
tion of a computational method for assessment of missense variants in hypertrophic cardiomyopathy.
Am J Hum Genet. 2011; 88(2): 183–192. https://doi.org/10.1016/j.ajhg.2011.01.011 PMID: 21310275
60. Hamasaki-Katagiri N, Salari R, Wu A, Qi Y, Schiller T, Filiberto AC, et al. A gene-specific method for
predicting hemophilia-causing point mutations. J Mol Biol. 2013; 425(21): 4023–4033. https://doi.org/
10.1016/j.jmb.2013.07.037 PMID: 23920358
61. Ruklisa D, Ware JS, Walsh R, Balding DJ, Cook SA. Bayesian models for syndrome- and gene-specific
probabilities of novel variant pathogenicity. Genome Med. 2015; 7(1): 5. https://doi.org/10.1186/
s13073-014-0120-4 PMID: 25649125
62. Crockett DK, Piccolo SR, Narus SP, Mitchell JA, Facelli JC. Computational Feature Selection and Clas-
sification of RET Phenotypic Severity. J Data Mining in Genom Proteomics. 2010; 1: 103.
63. Crockett DK, Piccolo SR, Ridge PG, Margraf RL, Lyon E, Williams MS, et al. Predicting phenotypic
severity of uncertain gene variants in the RET proto-oncogene. PLoS One. 2011; 6(3): e18380. https://
doi.org/10.1371/journal.pone.0018380 PMID: 21479187
64. Riera C, Lois S, Domı́nguez C, Fernandez-Cadenas I, Montaner J, Rodrı́guez-Sureda V, et al. Molecu-
lar damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological
mutations. Proteins. 2015; 83(1): 91–104. https://doi.org/10.1002/prot.24708 PMID: 25382311
65. Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, et al. Gene-Specific Variant Classifier (DPYD-
Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther.
2018; 104(4): 709–718. https://doi.org/10.1002/cpt.1020 PMID: 29327356
PLOS ONE Functional annotation of amino acid substitutions in epigenetic factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0244948 January 4, 2021 16 / 17
66. Qian D, Li S, Tian Y, Clifford JW, Sarver BAJ, Pesaran T, et al. A Bayesian framework for efficient and
accurate variant prediction. PLoS One. 2018; 13(9): e0203553. https://doi.org/10.1371/journal.pone.
0203553 PMID: 30212499
67. Niroula A, Vihinen M. Variation Interpretation Predictors: Principles, Types, Performance, and Choice.
Hum Mutat. 2016; 37(6): 579–597. https://doi.org/10.1002/humu.22987 PMID: 26987456
68. Sumonja N, Gemovic B, Veljkovic N, Perovic V. Automated feature engineering improves prediction of
protein-protein interactions. Amino Acids. 2019; 51(8): 1187–1200. https://doi.org/10.1007/s00726-
019-02756-9 PMID: 31278492
69. Mintseris J, Weng Z. Structure, function, and evolution of transient and obligate protein-protein interac-
tions. Proc Natl Acad Sci U S A. 2005; 102(31): 10930–10935. https://doi.org/10.1073/pnas.
0502667102 PMID: 16043700
70. Wu H, Zeng H, Dong A, Li F, He H, Senisterra G, et al. Structure of the catalytic domain of EZH2 reveals
conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
PLoS One. 2013; 8(12): e83737. https://doi.org/10.1371/journal.pone.0083737 PMID: 24367611
71. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering
EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet.
2010; 42(2): 181–185. https://doi.org/10.1038/ng.518 PMID: 20081860
PLOS ONE Functional annotation of amino acid substitutions in epigenetic factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0244948 January 4, 2021 17 / 17
